Boston Scientific credits its “category leadership strategy” for the company’s staggering 27 percent net income growth in the second quarter of 2016. CEO Mike Mahoney commented that Boston Scientific is aiming for “as much financial flexibility as we can have” and is on track to sustain momentum in its cardiac rhythm management business (CRM), which had lagged due to a lack of MRI-compatible products.
Baxter achieved better-than-expected second quarter sales and significant growth in its hospital products business. CEO José Almeida reported that the company is on track with its strategy outlined earlier this year, with continued growth resulting from a “disciplined focus” on portfolio management, innovation, and capital allocation for M&A.
Zimmer Biomet announced its plans to leverage the company’s years of consulting experience with its cultivated portfolio of technologies and analytical tools to create an “end-to-end” suite of clinical services called Signature Solutions. The intent of the service is to drive greater efficiency and improve patient outcomes in hospitals while working with the hospitals’ existing infrastructure.
Taking inspiration from bacteria, a team of Swiss scientists has developed a platform for developing microrobots that can be customized for various medical indications, such as delivering drugs or performing delicate surgical operations, including unblocking clogged arteries. These tiny robots shapeshift in response to heat and can be remotely controlled using electromagnetic fields.
Medtronic wants to generate $40 billion in free-cash-flow (FCF) by 2021, senior leadership said during a recent Investor Day event in New York City. The company’s strategies for future growth include therapy innovation, globalization, and a leadership position in value-based healthcare.
On the verge of acquisition by Abbott at the end of this year, St. Jude Medical announced that the company has met analysts’ performance estimates and achieved double digit sales growth, attributed by senior leadership to significant gains in its heart failure division. As in previous quarters, CEO Mike Rousseau noted that St. Jude’s cardiac rhythm management (CRM) business continues to be “challenged.”
Withings, a French digital health tech, has announced the commercial launch of Thermo, a non-invasive smart thermometer that takes temperature from the patient’s temple without touching the skin. Thermo, which will be available through Apple.com and Withings’ website, is Withings’ second product launch since its acquisition by Nokia Technologies earlier this year.
In an effort to “cut red tape and costs without cutting corners,” the European Commission is seeking more cooperation with the U.S. regulatory agencies in several key business sectors, including medical devices. The talks — which are part of the Transatlantic Trade and Investment Partnership (TTIP) — are ongoing and are expected to address unique device identifiers (UDIs), data submission, device standards, and exchange of information regarding noncompliant devices.
The Centers for Medicare and Medicaid Services (CMS), the FDA, and some members of Congress have advocated the inclusion of unique device identifier (UDI) numbers on insurance forms, including those used by Medicare. Leaders from both agencies say that collecting the data at the model level will help make medical devices safer, but industry advocates argue that the move is not financially feasible at this time.
Stryker has introduced a soft tissue fixation system, called SonicAnchor, for use in extremity repair surgeries that reattach tendons to bone. The technology liquefies the tip of the polymer implant using ultrasonic energy and the material flows into cancellous bone cavities, where it solidifies for a more stable hold.